Imunon adopts change-of-control severance agreements for top executives

• Imunon entered change-of-control severance agreements on May 1, 2026 covering CEO and President Stacy Lindborg, Chief Medical Officer Douglas Faller, General Counsel Susan Eylward.
• Termination without cause or resignation for good reason within one year after or four months before a change in control triggers lump-sum severance of 2.5x base salary plus target annual bonus for Lindborg, 1.5x for other covered executives.
• Benefits also include company-paid or reimbursed COBRA health premiums and life insurance for up to 24 months for Lindborg, up to 18 months for other executives.
• Agreements provide full acceleration of outstanding equity awards, with options generally remaining exercisable for original term subject to specified limits for post-change-in-control vesting.
• Payouts require a release of claims, with executives receiving greater of benefits if another severance arrangement applies, without duplication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-021019), on May 04, 2026, and is solely responsible for the information contained therein.